azd7009

**AZD7009** is an investigational small molecule antiarrhythmic agent developed primarily for the treatment of atrial fibrillation and atrial flutter. It acts predominantly on atrial electrophysiology, showing high efficacy in terminating and preventing reinduction of these arrhythmias with a low risk of proarrhythmic effects in both animal models and humans[1][6][8]. Mechanistically, AZD7009 exerts its effects through synergistic inhibition of multiple cardiac ion channels, including the rapid delayed rectifier potassium current (IKr/hERG), sodium current (INa/Nav1.5), transient outward potassium current (Ito/Kv4.3/KChIP2.2), and ultra rapid delayed rectifier potassium current (IKur/Kv1.5). This mixed ion channel blockade delays repolarization and increases refractoriness in atrial tissue while minimizing ventricular effects, which may underlie its favorable safety profile[4][6][8]. The drug was developed by AstraZeneca and reached phase II clinical trials for intravenous conversion of atrial fibrillation[2].

Other names

INAKALANTtert-butyl N-[2-[7-[(2S)-3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxa-3,7-diazabicyclo[3.3.1]nonan-3-yl]ethyl]carbamate864368-79-6335619-18-6